SG2057 structure
|
Common Name | SG2057 | ||
---|---|---|---|---|
CAS Number | 260417-62-7 | Molecular Weight | 584.662 | |
Density | 1.3±0.1 g/cm3 | Boiling Point | 820.0±65.0 °C at 760 mmHg | |
Molecular Formula | C33H36N4O6 | Melting Point | N/A | |
MSDS | N/A | Flash Point | 449.7±34.3 °C |
Use of SG2057SG2057 (DRG16) is a PBD dimer containing a pentyldioxy linkage which binds sequence selectively in the minor groove of DNA forming DNA interstrand and intrastrand cross-linked adducts. SG2057 is a highly active antitumor agent[1]. |
Name | (11aS,11a'S)-8,8'-[1,5-Pentanediylbis(oxy)]bis(7-methoxy-2-methylene-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one) |
---|---|
Synonym | More Synonyms |
Description | SG2057 (DRG16) is a PBD dimer containing a pentyldioxy linkage which binds sequence selectively in the minor groove of DNA forming DNA interstrand and intrastrand cross-linked adducts. SG2057 is a highly active antitumor agent[1]. |
---|---|
Related Catalog | |
Target |
Pyrrolobenzodiazepines |
In Vitro | SG2057 对一组人类肿瘤细胞系具有多重差异体外细胞毒性,平均 GI50 为 212 pM。SG2057 可高效地在细胞中产生 DNA 链间交联,这种交联快速形成并持续 48 小时[1]。 |
In Vivo | SG2057(5-60 μg/kg;静脉注射)在人肿瘤异种移植模型中表现出剂量依赖性抗肿瘤活性[1]。 Animal Model: Female NCr-nude mice injected with SKOV-3 cells[1] Dosage: 5 μg/kg, 10 μg/kg, 20 μg/kg, 30 μg/kg, 40 μg/kg, 50 μg/kg, 60 μg/kg Administration: i.v.; daily, once a week, or once every four days Result: Showed significant antitumor activity. |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 820.0±65.0 °C at 760 mmHg |
Molecular Formula | C33H36N4O6 |
Molecular Weight | 584.662 |
Flash Point | 449.7±34.3 °C |
Exact Mass | 584.263489 |
LogP | 2.75 |
Vapour Pressure | 0.0±3.0 mmHg at 25°C |
Index of Refraction | 1.647 |
(11aS,11a'S)-8,8'-[1,5-Pentanediylbis(oxy)]bis(7-methoxy-2-methylene-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one) |
5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one, 8,8'-[1,5-pentanediylbis(oxy)]bis[1,2,3,11a-tetrahydro-7-methoxy-2-methylene-, (11aS,11'aS)- |